Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Phase 1 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer.

Timeline

Start: 1998-04
Primary completion: 2000-03
Completion: 2000-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	arsenic trioxide	Small molecule	—	Intravenous

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Summary

Timeline

Drugs

Indications